Mesenchymal stem cells as feeder cells for pancreatic islet transplants.

Valeria Sordi, Lorenzo Piemonti

Research output: Contribution to journalArticle

Abstract

Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.

Original languageEnglish
Pages (from-to)132-143
Number of pages12
JournalThe review of diabetic studies : RDS
Volume7
Issue number2
Publication statusPublished - Jun 2010

Fingerprint

Feeder Cells
Mesenchymal Stromal Cells
Islets of Langerhans
Islets of Langerhans Transplantation
Transplants
Stem Cells
Therapeutics
Adult Stem Cells
Homologous Transplantation
Insulin-Secreting Cells
Stem Cell Transplantation
Immunosuppressive Agents
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Cell Survival
Maintenance
Pharmacology
Glucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mesenchymal stem cells as feeder cells for pancreatic islet transplants. / Sordi, Valeria; Piemonti, Lorenzo.

In: The review of diabetic studies : RDS, Vol. 7, No. 2, 06.2010, p. 132-143.

Research output: Contribution to journalArticle

@article{95f2a2701d8046b08d3e78fef21d2879,
title = "Mesenchymal stem cells as feeder cells for pancreatic islet transplants.",
abstract = "Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the {"}therapeutic plasticity{"} of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as {"}feeder{"} cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.",
author = "Valeria Sordi and Lorenzo Piemonti",
year = "2010",
month = "6",
language = "English",
volume = "7",
pages = "132--143",
journal = "Review of Diabetic Studies",
issn = "1613-6071",
publisher = "Society for Biomedical Diabetes Research",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells as feeder cells for pancreatic islet transplants.

AU - Sordi, Valeria

AU - Piemonti, Lorenzo

PY - 2010/6

Y1 - 2010/6

N2 - Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.

AB - Allogeneic islet transplantation serves as a source of insulin-secreting beta-cells for the maintenance of normal glucose levels and treatment of diabetes. However, limited availability of islets, high rates of islet graft failure, and the need for life-long non-specific immunosuppressive therapy are major obstacles to the widespread application of this therapeutic approach. To overcome these problems, pancreatic islet transplantation was recently suggested as a potential target of the "therapeutic plasticity" of adult stem cells. In fact, new results suggest that stem/precursor cells, and mesenchymal stem cells in particular, co-transplanted with islets can promote tissue engraftment and beta-cell survival via bystander mechanisms, mainly exerted by creating a milieu of cytoprotective and immunomodulatory molecules. This evidence consistently challenges the limited view that stem/precursor cells work exclusively through beta-cell replacement in diabetes therapy. It proposes that stem cells also act as "feeder" cells for islets, and supporter of graft protection, tissue revascularization, and immune acceptance. This article reviews the experience of using stem cell co-transplantation as strategy to improve islet transplantation. It highlights that comprehension of the mechanisms involved will help to identify new molecular targets and promote development of new pharmacological strategies to treat type 1 and type 2 diabetes patients.

UR - http://www.scopus.com/inward/record.url?scp=79952278886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952278886&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 132

EP - 143

JO - Review of Diabetic Studies

JF - Review of Diabetic Studies

SN - 1613-6071

IS - 2

ER -